Synonyms: PA-824 | PA824
pretomanid is an approved drug (FDA (2019), EMA (2020))
Compound class:
Synthetic organic
Comment: Pretomanid is a nitroimidazole-based antibacterial used for the treatment of multi-drug-resistant pulmonary tuberculosis [3]. It is active against replicating and non-replicating Mycobacterium tuberculosis [1]. Pretomanid was developed by the non-profit organisation TB Alliance (www.tballiance.org.za).
|
|
No information available. |
Summary of Clinical Use ![]() |
Pretomanid is administered orally. It is used in combination with bedaquiline and linezolid only for the treatment of patients with extensively drug resistant tuberculosis (XDR-TB), treatment-intolerant or nonresponsive multidrug resistant pulmonary tuberculosis (MDR-TB) [4]. This triple therapy, known as the BPaL regimen, received EU marketing authorisation in early August 2020, following FDA approval in 2019. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02333799 | A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis | Phase 3 Interventional | Global Alliance for TB Drug Development | 2 |
External links ![]() |
For extended ADME data see the following: Drugs.com |